ReviewJournal of Alzheimer's disease reports2020
Alzheimer's Disease and Herbal Combination Therapy: A Comprehensive Review.
Review in Journal of Alzheimer's disease reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Deep learning for intracranial hemorrhage detection and classification in brain CT scans: a systematic review and hybrid model approach.Frontiers in digital health · 2026Review
- Memory-Enhancing Effects of Dauricine in Swiss Mice: Possible Molecular Interventions Through In Vivo and In Silico Studies.Neuromolecular medicine · 2025Article
- Advances in Diagnostic Approaches for Alzheimer's Disease: From Biomarkers to Deep Learning Technology.CNS & neurological disorders drug targets · 2025Review
- Exploring shared therapeutic targets for Alzheimer's disease and glioblastoma using network pharmacology and protein-protein interaction approach.Frontiers in chemistry · 2025Article
- Enhancing Therapeutic Efficacy of Donepezil, an Alzheimer's Disease Drug, byPharmaceuticals (Basel, Switzerland) · 2024Article
- Deciphering the role of lipid metabolism-related genes in Alzheimer's disease: a machine learning approach integrating Traditional Chinese Medicine.Frontiers in endocrinology · 2024Article
- Role of BDNF Signaling in the Neuroprotective and Memory-enhancing Effects of Flavonoids in Alzheimer's Disease.CNS & neurological disorders drug targets · 2024Review
- Cell cycle arrest and apoptotic studies ofFrontiers in oncology · 2023Article
- Neuroprotective Effects of a Multi-Herbal Extract on Axonal and Synaptic DisruptionJournal of Alzheimer's disease reports · 2023Article
- The Multifaceted Role of Neuroprotective Plants in Alzheimer's Disease Treatment.Geriatrics (Basel, Switzerland) · 2022Review
- Flavonoids as Promising Neuroprotectants and Their Therapeutic Potential against Alzheimer's Disease.Oxidative medicine and cellular longevity · 2022Review
- Anticholinesterase activity ofFrontiers in pharmacology · 2022Article
- Synthesis, Computational Pharmacokinetics Report, Conceptual DFT-Based Calculations and Anti-Acetylcholinesterase Activity of Hydroxyapatite Nanoparticles Derived FromFrontiers in chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) was first described in 1907 and got its name after Alois Alzheimer, a German psychiatrist and neuropathologist. This disease starts slow, increasing gradually to worsen in the due course of time. AD is mainly characterized by the associated dementia, which is a decline of cognitive effects such as memory, praxis, and orientation. The dementia is further highlighted by the presence of psychological and behavioral symptoms. Additionally, AD is also associated with the multiple interconnected pathways linked neuropathological changes such as the formation of neurofibrillary tangles and amyloid-β plaques inside the brain. AD therapeutics have been of prime concern over the decades, resulting in the elucidation of promising therapeutic targets. The requirement of AD stage dependent optimized conditions has necessitated a combinatorial approach toward treatment. The priority in AD research has remained to develop disease-modifying and development-reducing drugs for treatment regimens followed during the early and later stages, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.